Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Treating chronic migraine with onabotulinumtoxinA (BotoxTM) may reduce the number of headache days when administered according to the National Institute for Health and Care Excellence guidelines, according to a prospective study published in the European Journal of Neurology.
The study included participants with chronic migraine with or without medication overuse headache who had received at least 2 treatments of onabotulinumtoxinA (n=200). Participants completed a headache diary and Headache Impact Test-6 score at baseline and throughout the treatment period.
After 2 treatments, 63.5% of participants (n=127) had at least a 30% reduction in headache days. Participants who continued the treatment up to 3 years reported a stable beneficial effect compared with baseline.
Among participants who responded to treatment, 53.5% (n=68) were reclassified as having episodic migraines. In 83.8% (n=57) of these individuals, headaches converted to an episodic migraine pattern after 6 months of follow-up.
The researchers did not observe any significant differences in treatment efficacy among participants treated with 155 U compared with those treated with >155 U.
Reference
Andreou AP, Trimboli M, Al-Kaisy A, et al. A prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE U.K. technology appraisal. [published online April 4, 2018] Eur J Neurol. doi:10.1111/ene.13657.
